On 11 August, CR Sanjiu released its 2016 half-year report. During the reporting period, the company posted operating income of RMB4.281 billion, among which, its pharmaceutical business recorded operating income of RMB4.052 billion, up 17.02% year-on-year; net profit attributable to shareholders of listed companies was RMB636 million, up 1.44% year-on-year; and net cash flow from business activities was RMB711 million, up 9.22% year-on-year.

In face of changes in industry conditions and the slowing economy, CR Sanjiu’s “13th Five-Year” strategy focuses on self-diagnosis and Chinese medicine prescription businesses, striving to grasp structural growth opportunities driven by consumption upgrade, increasing awareness of self-diagnosis, and value creation from Chinese medicine. Furthermore, it has been adjusting its business portfolio on a timely basis, optimising resources allocation and competitive strategies, thereby achieving stable growth in revenue size.

At the beginning of this year, the company invested heavily in marketing resources, resulting in a rise in sales expenses during this period. During the second quarter, based on the management theme of “Effectiveness and Efficiency”, the company strengthened its control over sales expenses, actively adjusted its product structure, and at the same time, increased the efficiency in utilising invested resources through streamlining its sales team management, achieving enhancement in business performance.